Related Experiment Videos

Allogeneic bone marrow transplantation for infantile globoid-cell leukodystrophy (Krabbe's disease)

Maurizio Caniglia1, Ippolita Rana, Rita Maria Pinto

  • 1Bone Marrow Transplant Unit, Hematology Division, Bambino Gesù Children's Hospital IRCCS, Piazza Sant'Onofrio, 400165 Rome, Italy. caniglia@opbg.net

Pediatric Transplantation
|October 23, 2002
PubMed

Insights

Early diagnosis is crucial for Krabbe's disease. Bone marrow transplantation (BMT) did not reverse neurological decline in a 4-month-old, highlighting the need for earlier intervention in Krabbe's disease.

Area of Science:

  • Neurology
  • Genetics
  • Pediatrics

Background:

  • Krabbe's disease is a rare, fatal genetic disorder affecting the nervous system.
  • Early-onset Krabbe's disease presents significant challenges for treatment and prognosis.
  • Allogeneic bone marrow transplantation (BMT) is a potential therapeutic option.

Observation:

  • A 4-month-old infant with early-onset Krabbe's disease and minimal central nervous system (CNS) involvement underwent BMT from her HLA-identical mother.
  • Post-BMT, the child experienced severe hypotonia, hydrocephalus, and neurological deterioration, succumbing 180 days later.
  • Successful engraftment and donor-derived enzyme activity (GALC) were confirmed post-transplantation.

Findings:

  • Despite successful BMT and chimerism, the patient's neurological deterioration was not reversed.
  • The study confirms that delayed diagnosis in early-onset Krabbe's disease limits the efficacy of BMT.

Implications:

  • This case underscores the critical importance of timely diagnosis and intervention for Krabbe's disease.
  • Further research is needed to determine if extremely early hematopoietic stem cell transplantation in the first weeks of life could be effective.
  • Investigating the optimal timing for BMT in Krabbe's disease is essential for improving patient outcomes.

Related Concept Videos